

NZEHE ESTITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)		
Balaji Venkataraman)		
Application No.: 10/635,928)	Examiner:	Not assigned
)		8
Filed: August 6, 2003)	Art Unit:	Not assigned
)		
For: VITAMIN COMPOSITIONS)		

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The citation of information on the attached Form PTO/SB/08 is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each cited item is enclosed.

The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,

Lisa C. Pavento Reg. No. 44,669

KILPATRICK STOCKTON LLP 1100 Peachtree Street Suite 2800 Atlanta, Georgia 30309-4530 (404) 815-6500

Our Docket: 52761-0110 (286146)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on September 2, 2003.

Lisa C. Pavento - Reg. No. 44,669

ATLLIB02 22985.1

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1895, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 1 of 6

Com	plete if Known	-
Application Number	10/635,928	
Filing Date	August 6, 2003	
First Nam d Invent r	Venkataraman	
Group Art Unit		
Examiner Name		
Attorney Docket Number	52761/286146	

		U.S. Patent Docume	nt	[Date of Publication of	Pp., Columns, Lines, Where
Examiner Initials	Cite No.1		nd Code ² if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Relevant Passages or Relevant Figures Appear
	1.	5,494,678		Paradissis, et al.	02-27-1996	
	2.	5,563,126		Allen, et al.	10-08-1996	
	3.	5,795,873		Allen	08-18-1998	
	4.	5,801,161		Merkus	09-01-1998	
	5.	5,932,624		Herbert	08-03-1999	
	6.	5,962,048		Register	10-05-1999	
	7.	6,039,978		Bangs, et al.	03-21-2000	
	8.	6,048,846	İ	Cochran	04-11-2000	
	9.	6,121,249		Weissman. et al.	09-19-2000	
	10.	6,127,370		Smith, et al.	10-03-2000	
	11.	6,207,651	B1	Allen, et al.	03-27-2001	
	12.	6,299,896	B1	Cooper, et al.	10-09-2001	
	13.	6,323,188	B1	Weissman	11-27-2001	
	14.	6,361,800	B1	Cooper, et al.	03-26-2002	
	15.	6,369,041	B2	Horrobin, et al.	04-09-2002	
	16.	6,479,545	B1	Levinson, et al.	11/12-2002	·
	17.	6,528,496	B1	Allen, et al.	03-04-2003	
	18.	2002/0010148	A1	Horrobin, et al.	01-24-2002	
	19.	2002/0136711	A1	Cochran	09-26-2002	
	20.	2002/0146463	A1	Clayton	10-10-2002	
	21.	2003/0049352	A1	Mehansho, et al.	03-13-2003	
	22.	2003/017136 (Abstract)	A1	Cruz, et al.	01-23-2003	

			_	FORE	IGN PATENT DOCUMENTS			
			Foreign Patent Docume	nt	Name of Detector or	Date of Publication	Pp., Columns, Lines,	
Examiner Initials	Cite	Office ³	Number⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T ⁶
	23.	EP	0366480 (Abstract)	B1	Bar Ilan University	08-24-1994	10,000	
	24.	wo	96/11009 (Abstract)	A1	UK	04-18-1996		
	25.	WO	98/01157 (Abstract)	A1	WWK Trust, Worsley, Andrew Peter	01-15-1998		
	26.	wo	2000/056295 (Abstract)	A2	Kilgowan Limited	09-28-2000		
	27.	wo	2001/056609 (Abstract)	A1	Germany	08-09-2001		
	28.	WO	2002/087593 (Abstract)	A1	Cobalz Limited	11-07-2002		

Examiner Signature	Date Considered	

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached. ATLLIB02 138545.2

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
rk Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet of 6

to respond to a collection of informa	to respond to a confection of information divises it contains a valid control right ber				
Complete if Known					
Application Numb r	10/635,928				
Filing Dat August 6, 2003					
First Named Inventor Venkataraman					
Group Art Unit					
Examiner Name					
Attorney Docket Number	52761/286146				

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Examine r Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	29.	ALTURA, BURTON M. and ALTURA, BELLA T., "Magnesium and Cardiovascular Biology: An	
		Important Link Between Cardiovascular Risk Factors and Atherogenesis," Cellular and Molecular	
		Biology Research, 1995, pp. 347-359, Vol. 41, No. 5.	
	30.	ANDERSSON, H.C., et al., "Long-Term Outcome in Treated Combined Methylmalonic Acidemia	
		and Homocystinemia," Genet Med, May-June 1999, pp. 146-150. (Abstract)	
	31.	APPEL, LAWRENCE, J., et al., "A Clinical Trial of the Effects of Dietary Patterns on Blood	ļ
		Pressure," N. Engl. J. Med, April 17, 1997, pp. 1117-1124, Vol. 336, No. 16.	
	32.	BASU, TAPAN K. and MANN, SARABJIT, "Vitamin B-6 Normalizes the Altered Sulfur Amino Acid	
		Status of Rats Fed Diets Containing Pharmacological Levels of Niacin Without Reducing Niacin's	
		Hypolipidemic Effects," J. Nutr., 1997, pp.117-121, Vol. 127.	
	33.	BLOOM, O. JOSH, et al., "Do Antioxidants (Vitamins C, E) Improve Outcomes in Patients With	<u> </u>
		Coronary Artery Disease?" J. Fam. Prac., November 2002, p. 978, Vol. 51, No. 11.	
	34.	BLUMBERG, A., et al., "Vitamin Nutrition in Patients on Continuous Ambulatory Peritoneal	
		Dialysis (CAPD)," Clin Nephrol, November 1983, pp. 244-250, Vol. 20, No. 5. (Abstract)	
	35.	BOUSHEY, CAROL J., et al., "A Quantitative Assessment of Plasma Homocysteine as a Risk	
		Factor for Vascular Disease," JAMA, October 4, 1995, pp. 1049-1057, Vol. 274, No. 13.	
	36.	BRATTSTROM, L. E., et al., "Folic Acid - An Innocuous Means to Reduce Plasma	
		Homocysteine," Scand J. Clin. Lab Invest., 1998, pp. 215-221, Vol. 48.	
	37.	BRATTSTROM, LARS E., et al., "Folic Acid Responsive Postmenopausal Homocysteinemia,	
		Metabolism," November 1985, pp. 1073-1077, Vol. 34, No. 11.	
	38.	BRATTSTROM, LARS, et al., "Impaired Homocysteine Metabolism in Early-Onset Cerebral and	+
	4	Peripheral Occlusive Arterial Disease," Atherosclerosis, 1990, pp. 51-60, Vol. 81.	
	39.	CAMPBELL, BRUCE G., et al., "Do Calcium Supplements Prevent Postmenopausal Osteoporotic	
		Fractures?" J of Fam Prac., March 2003, pp. 236-237, Vol. 52, No. 3.	
	40.	CHAMBERS, JOHN C., et al., "Improved Vascular Endothelial Function After Oral B Vitamins,"	+
		Circulation, Nov. 14, 2000, pp. 2479-2483, Vol. 102.	

Examiner Signature	Date Considered	

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO	St.
<u>е</u> т	Sallen

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 3 of 6

Com	plete if Known	
Application Number	10/635,928	
Filing Dat	August 6, 2003	
First Named Inventor	Venkataraman	
Group Art Unit		
Examiner Name		
Attorney Docket Number	52761/286146	_

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Examine r Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	41.	CHAN, P., et al., "Randomized, Double-Blind, Placebo-Controled Study of the Safety and Efficacy	
		of Vitamin B Complex in the Treatment of Nocturnal Leg Cramps in Elderly Patients with	
		Hypertension," J Clin Pharmacol., 1998, pp. 1151-1154, Vol. 38, No. 12. (Abstract)	
-	42.	DOSHI, SAGAR N., et al., "Folic Acid Improves Endothelial Function in Coronary Artery Disease	
		via Mechanisms Largely Independent of Homocysteine Lowering," Circulation, January 1/8, 2002,	
		pp. 23-26, Vol. 102.	
	43.	DUDMAN, NICHOLAS P. B., et al., "Homocysteinemia: Depressed Plasma Serine Levels,"	
		Metabolism, February 1987, pp. 198-201, Vol. 36, No. 2.	
	44.	ELIAN, et al., "Hydroxocobalamin Reduces Hyperhomocysteinemia in End-Stage Renal Disease,"	
		Metabolism, July 2002, pp. 881-886, Vol. 51. (Abstract)	
	45.	FANG, JAMES C., et al., "Effect of Vitamins C and E on Progression of Transplant-Associated	
		Arteriosclerosis: A Randomised Trial," The Lancet, March 30, 2002, pp. 1108-1113, Vol. 359.	
	46.	FRANKEN, D.G., et al., "Effect of Various Regimens of Vitamin B ₆ , and Folic Acid on Mild	
		Hyperhomocysteinaemia in Vascular Patients," J. Inher. Metab. Dis., 1994, pp. 159-162, Vol. 17.	
	47.	GABY, A. R., "Intravenous Nutrient Therapy: The Myers' Cocktail," Altern Med Rev, Oct. 2002,	
		pp. 389-403.	
	48.	GARG, REKKA, et al., "Niacin Treatment Increases Plasma Homocyst(e)ine Levels," Am Heart J.,	
		December 1999, pp 1082-1087, Vol. 138, No.6, Part 1.	
	49.	GOTTFRIES, C. G., "Pharmacological Treatment Strategies in Alzheimer Type Dementia," Eur	
		Neuropsychopharmacol, Nov. 1990, pp. 1-5. (Abstract)	
	50.	HAIDARI, MEHRAN, et al., "Enhanced Susceptibility to Oxidation and Diminished Vitamin E	
		Content of LDL from Patients with Stable Coronary Artery Disease," Clinical Chemistry, 2001, pp.	
		1234-1240, Vol. 47, No.7.	
	51.	HARPEY, JEAN-PAUL, et al., "Homocystinuria Caused by 5,10-Methylenetetrahydrofolate	
		Reductase Deficiency: A Case in an Infant Responding to Methionine, Folinic Acid, Pyridoxine,	
		and Vitamin B ₁₂ Therapy," J Pediatrics, February 1981, pp. 275-278, Vol. 98, No. 2.	

Examiner Signature	Date Considered	

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number

Under the Paperwork Reduction Act of 1995 no persons are required to

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 4 of 6

to respond to a collection of information unless it contains a valid ONB control number		
Compl te if Known		
Application Numb r	10/635,928	
Filing Dat	August 6, 2003	
First Named Inv ntor	Venkataraman	
Group Art Unit		
Examiner Name		
Attorney Docket Number	52761/286146	

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Examine r Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
	52.	HEINECKE, JAY W., "Is the Emperor Wearing Clothes?" Arterioscler Thromb Vasc Biol., August	
		2001, pp. 1261-1264, Vol. 21.	
	53.	HEINONEN, O.P., et al., "The Effect of Vitamin E and Beta Carotene on the Incidence of Lung	
		Cancer and Other Cancers in Male Smokers," TN Engl J Med, April 14, 1994, pp. 1029-1035, Vol.	
		330, No. 15.	
	54.	HENKIN, YAAKOV, et al., "Niacin Revisited: Clinical Observations on an Important But	1
		Underutilized Drug," Am J Med, September 1991, pp. 239-246, Vol. 91.	
	55.	HERBERT, V., "The Inhibition and Promotion of Cancers by Folic Acid, Vitamin B ₁₂ , and their	†
		Antagonists," American Chemical Society (ACS Symposium series), 1985, pp. 32-36, Vol. 277.	
_	56.	KAUL, NALINI, et al., "α-Tocopherol and Atherosclerosis," E.B.M., 2001, pp. 5-12, Vol. 226.	†
	57.	KLERK, M., "Effect of Homocysteine Reduction by B-Vitamin Supplementation on Markers of	
		Clotting Activation," Thromb Haemost, Aug. 2002, pp. 230-235, Vol. 88.	İ
	58.	LIAO, FANGZI, et al., "Is Low Magnesium Concentration a Risk Factor For Coronary Heart	1
		Disease? The Atherosclerosis Risk in Communities (ARIC) Study," Am Heart J, September 1998,	
		pp. 480-490, Vol. 136, No. 3.	
	59.	MARCHESONI, D., et al., "Menopause Rather than Estrogen Modifies Plasma Homocysteine	-
		Levels," International Journal of Gynecology and Obstetrics, 2003, pp. 293-297, Vol. 81.	
	60.	MASON, JB and MILLER, J.W., "The Effects of Vitamins B12, B6, and Folate on Blood	
		Homocysteine Levels," Ann NY Acad Sci., Sept. 30, 1992, pp. 197-203.	
	61.	NILSSON, K., et al., "Treatment of Cobalamin Deficiency in Dementia, Evaluated Clinically and	
		With Cerebral Blood Flow Measurements," Aging (Milano), June 2000, pp. 199-207, Vol. 12.	
	62.	OLSZEWSKI, ANDRZEJ J., et al., "Reduction of Plasma Lipid and Homocysteine Levels by	
		Pyridoxine, Folate, Cobalamin, Choline, Riboflavin, and Troxerutin in Atherosclerosis,"	
		Atherosclersis, 1989, pp. 1-6, Vol. 75.	
	63.	ROSSI, A., et al., "Early-Onset Combined Methymalonic Aciduria and Homocystinuria:	1
		Neuroradiologic Findings," Am J. Neuroradiol, March 2001, pp. 554-563, Vol. 22.	

Examiner		Date	
Signature		l	
Oignature	·	Considered	

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwok Reduction Act of 1985 no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 5 of 6

Com	plete if Known	
Application Number	10/635,928	
Filing Date	August 6, 2003	
First Named Inventor	Venkataraman	
Group Art Unit		
Examiner Name		
Attorney Docket Number	52761/286146	

Examine file (hock, magazine, journal, serial, symposium, catalog, etc.), date, page(s), votume-issue number(s), publisher, city and/or country where published 64. ROSSOUW, JACQUES E., et al., "Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women" JAMA, July 17, 2002, pp. 321-333, Vol. 288, No. 3. 65. SCHNYDER, GUIDO, et al., "Effect of Homocysteine-Lowering Therapy with Folic Acid, Vitamin B12, and Vitamin B6 on Clinical Outcome After Percutaneous Coronary Intervention," JAMA, August 28, 2002, pp. 973-979, Vol. 288, No. 8. 66. SHECHTER, MICHAEL, et al., "Oral Magnesium Supplementation Inhibits Platelet-Dependent Thrombosis in Patients With Coronary Artery Disease," Am J Cardio., July 15, 1999, pp. 152-156 Vol. 84. 67. SHECHTER, MICHAEL, et al., "Oral Magnesium Therapy Improves Endothelial Function in Patients with Coronary Artery Disease," Circulation, November 7, 2000, pp. 2351-2358, Vol. 102 68. STABLER, et al., "Elevations of Serum Cystathionine and Homocysteine in Vitamin B-6, Folate and Cobalamin Deficient Rats," Blood, 1994, pp. 118A, Vol 84, No. 10, Suppl. 1. 69. STAMPER, MEIR J. and MALINOW, M. RENE, "Can Lowering Homocysteine Levels Reduce Cardiovascular Risk?" The New England Journal of Medicine, Feb. 2, 1995, pp. 328-329, Vol. 332, No. 5. 70. STEIN, JAMES H. and MCBRIDE, PATRICK E., "Hyperhomocysteinemia and Atherosclerotic Vascular Disease," Arch Intern Med., June 22, 1998; pp. 1301-1306, Vol. 158. STEPHENS, NIGEL G., et al., "Randomised Controlled Trial of Vitamin E in Patients with Coronary Disease: Cambridge Heart Antioxidant Study (CHAOS)," The Lancet, March 23, 1996 pp. 781-786, Vol. 347.	
Postmenopausal Women" JAMA, July 17, 2002, pp. 321-333, Vol. 288, No. 3. 65. SCHNYDER, GUIDO, et al., "Effect of Homocysteine-Lowering Therapy with Folic Acid, Vitamir B ₁₂ , and Vitamin B ₆ on Clinical Outcome After Percutaneous Coronary Intervention," JAMA, August 28, 2002, pp. 973-979, Vol. 288, No. 8. 66. SHECHTER, MICHAEL, et al., "Oral Magnesium Supplementation Inhibits Platelet-Dependent Thrombosis in Patients With Coronary Artery Disease," Am J Cardio., July 15, 1999, pp. 152-156 Vol. 84. 67. SHECHTER, MICHAEL, et al., "Oral Magnesium Therapy Improves Endothelial Function in Patients with Coronary Artery Disease," Circulation, November 7, 2000, pp. 2351-2358, Vol. 102 68. STABLER, et al., "Elevations of Serum Cystathionine and Homocysteine in Vitamin B-6, Folate and Cobalamin Deficient Rats," Blood, 1994, pp. 118A, Vol 84, No. 10, Suppl. 1. 69. STAMPER, MEIR J. and MALINOW, M. RENE, "Can Lowering Homocysteine Levels Reduce Cardiovascular Risk?" The New England Journal of Medicine, Feb. 2, 1995, pp. 328-329, Vol. 332, No. 5. 70. STEIN, JAMES H. and MCBRIDE, PATRICK E., "Hyperhomocysteinemia and Atherosclerotic Vascular Disease," Arch Intern Med., June 22, 1998; pp. 1301-1306, Vol. 158. 71. STEPHENS, NIGEL G., et al., "Randomised Controlled Trial of Vitamin E in Patients with Coronary Disease: Cambridge Heart Antioxidant Study (CHAOS)," The Lancet, March 23, 1996 pp. 781-786, Vol. 347.	T ²
 SCHNYDER, GUIDO, <i>et al.</i>, "Effect of Homocysteine-Lowering Therapy with Folic Acid, Vitamir B₁₂, and Vitamin B₆ on Clinical Outcome After Percutaneous Coronary Intervention," JAMA, August 28, 2002, pp. 973-979, Vol. 288, No. 8. G6. SHECHTER, MICHAEL, <i>et al.</i>, "Oral Magnesium Supplementation Inhibits Platelet-Dependent Thrombosis in Patients With Coronary Artery Disease," Am J Cardio., July 15, 1999, pp. 152-156 Vol. 84. G7. SHECHTER, MICHAEL, <i>et al.</i>, "Oral Magnesium Therapy Improves Endothelial Function in Patients with Coronary Artery Disease," Circulation, November 7, 2000, pp. 2351-2358, Vol. 102 G8. STABLER, <i>et al.</i>, "Elevations of Serum Cystathionine and Homocysteine in Vitamin B-6, Folate and Cobalamin Deficient Rats," Blood, 1994, pp. 118A, Vol 84, No. 10, Suppl. 1. G9. STAMPER, MEIR J. and MALINOW, M. RENE, "Can Lowering Homocysteine Levels Reduce Cardiovascular Risk?" The New England Journal of Medicine, Feb. 2, 1995, pp. 328-329, Vol. 332, No. 5. T0. STEIN, JAMES H. and MCBRIDE, PATRICK E., "Hyperhomocysteinemia and Atherosclerotic Vascular Disease," Arch Intern Med., June 22, 1998; pp. 1301-1306, Vol. 158. T1. STEPHENS, NIGEL G., <i>et al.</i>, "Randomised Controlled Trial of Vitamin E in Patients with Coronary Disease: Cambridge Heart Antioxidant Study (CHAOS)," The Lancet, March 23, 1996 pp. 781-786, Vol. 347. 	
B ₁₂ , and Vitamin B ₆ on Clinical Outcome After Percutaneous Coronary Intervention," JAMA, August 28, 2002, pp. 973-979, Vol. 288, No. 8. 66. SHECHTER, MICHAEL, et al., "Oral Magnesium Supplementation Inhibits Platelet-Dependent Thrombosis in Patients With Coronary Artery Disease," Am J Cardio., July 15, 1999, pp. 152-156, Vol. 84. 67. SHECHTER, MICHAEL, et al., "Oral Magnesium Therapy Improves Endothelial Function in Patients with Coronary Artery Disease," Circulation, November 7, 2000, pp. 2351-2358, Vol. 102 68. STABLER, et al., "Elevations of Serum Cystathionine and Homocysteine in Vitamin B-6, Folate and Cobalamin Deficient Rats," Blood, 1994, pp. 118A, Vol 84, No. 10, Suppl. 1. 69. STAMPER, MEIR J. and MALINOW, M. RENE, "Can Lowering Homocysteine Levels Reduce Cardiovascular Risk?" The New England Journal of Medicine, Feb. 2, 1995, pp. 328-329, Vol. 332, No. 5. 70. STEIN, JAMES H. and MCBRIDE, PATRICK E., "Hyperhomocysteinemia and Atherosclerotic Vascular Disease," Arch Intern Med., June 22, 1998; pp. 1301-1306, Vol. 158. 71. STEPHENS, NIGEL G., et al., "Randomised Controlled Trial of Vitamin E in Patients with Coronary Disease: Cambridge Heart Antioxidant Study (CHAOS)," The Lancet, March 23, 1996 pp. 781-786, Vol. 347.	
 August 28, 2002, pp. 973-979, Vol. 288, No. 8. 66. SHECHTER, MICHAEL, et al., "Oral Magnesium Supplementation Inhibits Platelet-Dependent Thrombosis in Patients With Coronary Artery Disease," Am J Cardio., July 15, 1999, pp. 152-156 Vol. 84. 67. SHECHTER, MICHAEL, et al., "Oral Magnesium Therapy Improves Endothelial Function in Patients with Coronary Artery Disease," Circulation, November 7, 2000, pp. 2351-2358, Vol. 102 68. STABLER, et al., "Elevations of Serum Cystathionine and Homocysteine in Vitamin B-6, Folate and Cobalamin Deficient Rats," Blood, 1994, pp. 118A, Vol 84, No. 10, Suppl. 1. 69. STAMPER, MEIR J. and MALINOW, M. RENE, "Can Lowering Homocysteine Levels Reduce Cardiovascular Risk?" The New England Journal of Medicine, Feb. 2, 1995, pp. 328-329, Vol. 332, No. 5. 70. STEIN, JAMES H. and MCBRIDE, PATRICK E., "Hyperhomocysteinemia and Atherosclerotic Vascular Disease," Arch Intern Med., June 22, 1998; pp. 1301-1306, Vol. 158. 71. STEPHENS, NIGEL G., et al., "Randomised Controlled Trial of Vitamin E in Patients with Coronary Disease: Cambridge Heart Antioxidant Study (CHAOS)," The Lancet, March 23, 1996 pp. 781-786, Vol. 347. 	
 66. SHECHTER, MICHAEL, et al., "Oral Magnesium Supplementation Inhibits Platelet-Dependent Thrombosis in Patients With Coronary Artery Disease," Am J Cardio., July 15, 1999, pp. 152-156 Vol. 84. 67. SHECHTER, MICHAEL, et al., "Oral Magnesium Therapy Improves Endothelial Function in Patients with Coronary Artery Disease," Circulation, November 7, 2000, pp. 2351-2358, Vol. 102 68. STABLER, et al., "Elevations of Serum Cystathionine and Homocysteine in Vitamin B-6, Folate and Cobalamin Deficient Rats," Blood, 1994, pp. 118A, Vol 84, No. 10, Suppl. 1. 69. STAMPER, MEIR J. and MALINOW, M. RENE, "Can Lowering Homocysteine Levels Reduce Cardiovascular Risk?" The New England Journal of Medicine, Feb. 2, 1995, pp. 328-329, Vol. 332, No. 5. 70. STEIN, JAMES H. and MCBRIDE, PATRICK E., "Hyperhomocysteinemia and Atherosclerotic Vascular Disease," Arch Intern Med., June 22, 1998; pp. 1301-1306, Vol. 158. 71. STEPHENS, NIGEL G., et al., "Randomised Controlled Trial of Vitamin E in Patients with Coronary Disease: Cambridge Heart Antioxidant Study (CHAOS)," The Lancet, March 23, 1996 pp. 781-786, Vol. 347. 	
Thrombosis in Patients With Coronary Artery Disease," Am J Cardio., July 15, 1999, pp. 152-156 Vol. 84. 67. SHECHTER, MICHAEL, et al., "Oral Magnesium Therapy Improves Endothelial Function in Patients with Coronary Artery Disease," Circulation, November 7, 2000, pp. 2351-2358, Vol. 102 68. STABLER, et al., "Elevations of Serum Cystathionine and Homocysteine in Vitamin B-6, Folate and Cobalamin Deficient Rats," Blood, 1994, pp. 118A, Vol 84, No. 10, Suppl. 1. 69. STAMPER, MEIR J. and MALINOW, M. RENE, "Can Lowering Homocysteine Levels Reduce Cardiovascular Risk?" The New England Journal of Medicine, Feb. 2, 1995, pp. 328-329, Vol. 332, No. 5. 70. STEIN, JAMES H. and MCBRIDE, PATRICK E., "Hyperhomocysteinemia and Atherosclerotic Vascular Disease," Arch Intern Med., June 22, 1998; pp. 1301-1306, Vol. 158. 71. STEPHENS, NIGEL G., et al., "Randomised Controlled Trial of Vitamin E in Patients with Coronary Disease: Cambridge Heart Antioxidant Study (CHAOS)," The Lancet, March 23, 1996 pp. 781-786, Vol. 347.	
 Vol. 84. 67. SHECHTER, MICHAEL, et al., "Oral Magnesium Therapy Improves Endothelial Function in Patients with Coronary Artery Disease," Circulation, November 7, 2000, pp. 2351-2358, Vol. 102 68. STABLER, et al., "Elevations of Serum Cystathionine and Homocysteine in Vitamin B-6, Folate and Cobalamin Deficient Rats," Blood, 1994, pp. 118A, Vol 84, No. 10, Suppl. 1. 69. STAMPER, MEIR J. and MALINOW, M. RENE, "Can Lowering Homocysteine Levels Reduce Cardiovascular Risk?" The New England Journal of Medicine, Feb. 2, 1995, pp. 328-329, Vol. 332, No. 5. 70. STEIN, JAMES H. and MCBRIDE, PATRICK E., "Hyperhomocysteinemia and Atherosclerotic Vascular Disease," Arch Intern Med., June 22, 1998; pp. 1301-1306, Vol. 158. 71. STEPHENS, NIGEL G., et al., "Randomised Controlled Trial of Vitamin E in Patients with Coronary Disease: Cambridge Heart Antioxidant Study (CHAOS)," The Lancet, March 23, 1996 pp. 781-786, Vol. 347. 	-
 67. SHECHTER, MICHAEL, et al., "Oral Magnesium Therapy Improves Endothelial Function in Patients with Coronary Artery Disease," Circulation, November 7, 2000, pp. 2351-2358, Vol. 102 68. STABLER, et al., "Elevations of Serum Cystathionine and Homocysteine in Vitamin B-6, Folate and Cobalamin Deficient Rats," Blood, 1994, pp. 118A, Vol 84, No. 10, Suppl. 1. 69. STAMPER, MEIR J. and MALINOW, M. RENE, "Can Lowering Homocysteine Levels Reduce Cardiovascular Risk?" The New England Journal of Medicine, Feb. 2, 1995, pp. 328-329, Vol. 332, No. 5. 70. STEIN, JAMES H. and MCBRIDE, PATRICK E., "Hyperhomocysteinemia and Atherosclerotic Vascular Disease," Arch Intern Med., June 22, 1998; pp. 1301-1306, Vol. 158. 71. STEPHENS, NIGEL G., et al., "Randomised Controlled Trial of Vitamin E in Patients with Coronary Disease: Cambridge Heart Antioxidant Study (CHAOS)," The Lancet, March 23, 1996 pp. 781-786, Vol. 347. 	,
Patients with Coronary Artery Disease," Circulation, November 7, 2000, pp. 2351-2358, Vol. 102 68. STABLER, et al., "Elevations of Serum Cystathionine and Homocysteine in Vitamin B-6, Folate and Cobalamin Deficient Rats," Blood, 1994, pp. 118A, Vol 84, No. 10, Suppl. 1. 69. STAMPER, MEIR J. and MALINOW, M. RENE, "Can Lowering Homocysteine Levels Reduce Cardiovascular Risk?" The New England Journal of Medicine, Feb. 2, 1995, pp. 328-329, Vol. 332, No. 5. 70. STEIN, JAMES H. and MCBRIDE, PATRICK E., "Hyperhomocysteinemia and Atherosclerotic Vascular Disease," Arch Intern Med., June 22, 1998; pp. 1301-1306, Vol. 158. 71. STEPHENS, NIGEL G., et al., "Randomised Controlled Trial of Vitamin E in Patients with Coronary Disease: Cambridge Heart Antioxidant Study (CHAOS)," The Lancet, March 23, 1996 pp. 781-786, Vol. 347.	
 STABLER, et al., "Elevations of Serum Cystathionine and Homocysteine in Vitamin B-6, Folate and Cobalamin Deficient Rats," Blood, 1994, pp. 118A, Vol 84, No. 10, Suppl. 1. STAMPER, MEIR J. and MALINOW, M. RENE, "Can Lowering Homocysteine Levels Reduce Cardiovascular Risk?" The New England Journal of Medicine, Feb. 2, 1995, pp. 328-329, Vol. 332, No. 5. STEIN, JAMES H. and MCBRIDE, PATRICK E., "Hyperhomocysteinemia and Atherosclerotic Vascular Disease," Arch Intern Med., June 22, 1998; pp. 1301-1306, Vol. 158. STEPHENS, NIGEL G., et al., "Randomised Controlled Trial of Vitamin E in Patients with Coronary Disease: Cambridge Heart Antioxidant Study (CHAOS)," The Lancet, March 23, 1996 pp. 781-786, Vol. 347. 	
 and Cobalamin Deficient Rats," Blood, 1994, pp. 118A, Vol 84, No. 10, Suppl. 1. 69. STAMPER, MEIR J. and MALINOW, M. RENE, "Can Lowering Homocysteine Levels Reduce Cardiovascular Risk?" The New England Journal of Medicine, Feb. 2, 1995, pp. 328-329, Vol. 332, No. 5. 70. STEIN, JAMES H. and MCBRIDE, PATRICK E., "Hyperhomocysteinemia and Atherosclerotic Vascular Disease," Arch Intern Med., June 22, 1998; pp. 1301-1306, Vol. 158. 71. STEPHENS, NIGEL G., et al., "Randomised Controlled Trial of Vitamin E in Patients with Coronary Disease: Cambridge Heart Antioxidant Study (CHAOS)," The Lancet, March 23, 1996 pp. 781-786, Vol. 347. 	
 69. STAMPER, MEIR J. and MALINOW, M. RENE, "Can Lowering Homocysteine Levels Reduce Cardiovascular Risk?" The New England Journal of Medicine, Feb. 2, 1995, pp. 328-329, Vol. 332, No. 5. 70. STEIN, JAMES H. and MCBRIDE, PATRICK E., "Hyperhomocysteinemia and Atherosclerotic Vascular Disease," Arch Intern Med., June 22, 1998; pp. 1301-1306, Vol. 158. 71. STEPHENS, NIGEL G., et al., "Randomised Controlled Trial of Vitamin E in Patients with Coronary Disease: Cambridge Heart Antioxidant Study (CHAOS)," The Lancet, March 23, 1996 pp. 781-786, Vol. 347. 	
Cardiovascular Risk?" The New England Journal of Medicine, Feb. 2, 1995, pp. 328-329, Vol. 332, No. 5. 70. STEIN, JAMES H. and MCBRIDE, PATRICK E., "Hyperhomocysteinemia and Atherosclerotic Vascular Disease," Arch Intern Med., June 22, 1998; pp. 1301-1306, Vol. 158. 71. STEPHENS, NIGEL G., et al., "Randomised Controlled Trial of Vitamin E in Patients with Coronary Disease: Cambridge Heart Antioxidant Study (CHAOS)," The Lancet, March 23, 1996 pp. 781-786, Vol. 347.	
 332, No. 5. 70. STEIN, JAMES H. and MCBRIDE, PATRICK E., "Hyperhomocysteinemia and Atherosclerotic Vascular Disease," Arch Intern Med., June 22, 1998; pp. 1301-1306, Vol. 158. 71. STEPHENS, NIGEL G., et al., "Randomised Controlled Trial of Vitamin E in Patients with Coronary Disease: Cambridge Heart Antioxidant Study (CHAOS)," The Lancet, March 23, 1996 pp. 781-786, Vol. 347. 	
 STEIN, JAMES H. and MCBRIDE, PATRICK E., "Hyperhomocysteinemia and Atherosclerotic Vascular Disease," Arch Intern Med., June 22, 1998; pp. 1301-1306, Vol. 158. STEPHENS, NIGEL G., et al., "Randomised Controlled Trial of Vitamin E in Patients with Coronary Disease: Cambridge Heart Antioxidant Study (CHAOS)," The Lancet, March 23, 1996 pp. 781-786, Vol. 347. 	
Vascular Disease," Arch Intern Med., June 22, 1998; pp. 1301-1306, Vol. 158. 71. STEPHENS, NIGEL G., et al., "Randomised Controlled Trial of Vitamin E in Patients with Coronary Disease: Cambridge Heart Antioxidant Study (CHAOS)," The Lancet, March 23, 1996 pp. 781-786, Vol. 347.	
71. STEPHENS, NIGEL G., et al., "Randomised Controlled Trial of Vitamin E in Patients with Coronary Disease: Cambridge Heart Antioxidant Study (CHAOS)," The Lancet, March 23, 1996 pp. 781-786, Vol. 347.	-
Coronary Disease: Cambridge Heart Antioxidant Study (CHAOS)," The Lancet, March 23, 1996 pp. 781-786, Vol. 347.	
pp. 781-786, Vol. 347.	
72. STIPANUK, MARTHA H., "Metabolism of Sulfur-Containing Amino Acids," Ann. Rev. Nutr., 1986	+-
pp. 179-209, Vol. 6.	
73. TICE, JEFFREY A., et al., "Cost-effectiveness of Vitamin Therapy to Lower Plasma Homocystein	e
Levels for the Prevention of Coronary Heart Disease: Effect of Grain Fortification and Beyond,"	
JAMA, August 22/29, 2001, pp. 936-943, Vol. 286.	

Examiner Signature	Date Considered	

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

SEP 1 1 2003 Under the Paperwook Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet of 6

Complete if Kn wn		
Application Numb r	10/635,928	
Filing Date	August 6, 2003	
First Nam d Inv ntor	Venkataraman	
Group Art Unit		
Examiner Name		
Attorney Docket Number	52761/286146	

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Examine r Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
	74.	UELAND, P.M. and REFSUM, H., "Plasma Homocysteine, A Risk Factor For Premature Vascular	
		Disease. Plasma Levels in Healthy Person; During Pathologic Conditions and Drug Therapy,"	
		Nord Med., 1989, pp. 293-308, Vol. 104, No. 11. (Abstract)	
	75.	VALAGUSSA, F., et al., "Dietary Supplementation With N-3 Polyunsaturated Fatty Acids and	1.
	1	Vitamin E After Myocardial Infarction: Results of the GISSI-Prevenzione Trial," The Lancet,	1
		August 7, 1999, pp. 447-455, Vol. 354.	
	76.	VAN DER KUY, et al., "Hydroxocobalamin, A Nitric Oxide Scavenger, In the Prophylaxis of	
		Migraine: An Open, Pilot Study," Cephalalgia Sept. 2002, pp. 513-519, Vol. 22, No. 7,.	
	77.	VERHAAR, MARIANNE C., et al., "Effects of Oral Folic Acid Supplementation on Endothelial	
		Function in Familial Hypercholesterolemia," Circulation, July 27, 1999, pp. 335-338, Vol. 100.	
	78.	VIVANCO, N., et al., "Treatment of Anorexia Nervosa," Rev Med Chil, 1992, pp. 69-75, Vol. 120.	
		(Abstract)	
	79.	WATERS, DAVID D., et al., "Effects of Hormone Replacement Therapy and Antioxidant Vitamin	1
		Supplements on Coronary Atherosclerosis in Postmenopausal Women," JAMA, November 20,	
		2002, pages 2432-3440, Vol 288, No. 19.	
	80.	YANG, CHUN-YUH, "Calcium and Magnesium in Drinking Water and Risk of Death from	
		Cerebrovascular Disease," Stroke, 1998, pp. 411-414, Vol. 29.	

Examiner	Date
Signature	Considered
	Considered

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.